The present invention relates to a pharmaceutical formulation intended for oral administration containing a solvate or addition salt or its pharmacologically acceptable synthetic oligosaccharides include monosaccharide units 18 1, have therapeutic activity, wherein the formulation: up to 5% by weight relative to the total weight of a) the formulation, preferably, the synthetic oligosaccharides in an amount of up to 1 wt% (A), b) a formulation based on the total weight of the formulation 80% from 50, advantageously, the total weight of the lipophilic phase comprising an amount of 70 wt% 50, of triglycerides of fatty acids based on the total weight of the formulation (B), c) a formulation based on the total weight from 10 to 30% by weight with respect, preferably, is an amount of 30% by weight 15, the partial esters of fatty acids and polyols based on the total weight of the formulation, the lipophilic surface of at least one having an HLB value less than 7 and up to 20% by weight relative to the total weight of active agent (C), d) the formulation, preferably, at least one hydrophilic, higher than 7 in an amount of up to 15 wt%, an HLB on the total weight of the formulation and may contain a surfactant (D), by e) optionally, up to 15% by weight based on the total weight of the formulation, preferably in an amount of up to 10 wt%, at least 1, based on the total weight of the formulation from 0 to 30% by weight relative to the total weight of the hydrophilic solvent Tsu (E), f) The formulation, preferably, physical stabilizers and / or chemical from 0 to 20% by weight based on the total weight of the formulation A content of the (F),, where the formulation is in the form of a microemulsion or reverse phase emulsion, when containing hydrophilic solvent one (E), the physical stabilizer is present, it dioxide least is silicon.本発明は、1から18個のモノサッカリド単位を含み、治療活性を有する合成オリゴサッカリド、またはその薬理学的に許容される付加塩もしくは溶媒和物を含有する経口投与を意図した医薬製剤に関し、ここで、この製剤は:a)製剤の総重量に対して5重量%まで、有利には、製剤の総重量に対して1重量%までの量の合成オ
